Showing results (391-400 of 409) with videos related to
Sort By:
Pageof 41
Nature Communications|August 10, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clonesA M Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, et al.BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.Molecular Cell|June 10, 2020
Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 NucleaseAlejandro Álvarez-Quilón, Jessica L Wojtaszek, Marie-Claude Mathieu, et al.Frontiers in Pediatrics|January 24, 2022
Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)-Rationale and DesignDerek L Tran, Hannah Gibson, Andrew J Maiorana, et al.Transfusion|May 18, 2016
A targeted immunomic approach identifies diagnostic antigens in the human pathogen Babesia microtiEmmanuel Cornillot, Amina Dassouli, Niseema Pachikara, et al.Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.European Urology Oncology|November 29, 2024
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.Theranostics|October 14, 2020
First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancersAndrew M Scott, Timothy Akhurst, Fook-Thean Lee, et al.The EMBO Journal|March 14, 2013
Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative diseaseReza Sharifi, Rosa Morra, C Denise Appel, et al.Pageof 41